Most Awaited Q3 Sale is back. Upto 30% discount on every report.

Myelodysplastic Syndrome (MDS) Treatment Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 June 05
SKU : PH2678
180 pages
Report Summary
Table of Content
List of Tables & Figures

Myelodysplastic Syndrome (MDS) Treatment Market is segmented By Treatment Type (Stem Cell Transplant, Immune Treatments, Chemotherapy (Hypomethylating Agents (Azacitidine (Vidaza), Decitabine (Dacogen)), Immunomodulatory Drugs (Lenalidomide (Revlimid), Others), Anti-anemics (Luspatercept-AAMT (REBLOZYL®), Others), Others (Cytarabine (Cytosar-U), Daunorubicin (Cerubidine), Idarubicin (Idamycin), INQOVI® (ASTX727))), Growth factors, Others), By End-User (Hospitals, Specialty Clinics, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030 


Myelodysplastic Syndrome (MDS) Treatment Market Overview

The Global Myelodysplastic Syndrome (MDS) Treatment Market reached US$ 3,065.5 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 6,059.5 million by 2030. The global myelodysplastic syndrome treatment market is expected to exhibit a CAGR of 9.1% during the forecast period (2023-2030). There is a growing market trend to expand the market as a result of myelodysplastic syndrome’s increasing incidence and prevalence around the world.

The likelihood of developing myelodysplastic syndrome rises with age, creating a bigger patient population in need of care.  

Treatment options have increased with the introduction of targeted medications that are specific to specific genetic defects and mutations linked to MDS. The myelodysplastic syndrome treatment market is anticipated to be driven by these medicines, which have demonstrated encouraging results in clinical trials. 


Myelodysplastic Syndrome (MDS) Treatment Market Scope





Size Available for Years


Forecast Period


Data Availability

Value (US$) 

Segments Covered

Treatment Type, End User, and Region

Regions Covered

North America, Europe, Asia-Pacific, South America, and Middle East & Africa

Fastest Growing Region


Largest Region

North America

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Orthopedic Surgery key Insights.


For more insights - Download the Sample


Myelodysplastic Syndrome (MDS) Treatment Market Dynamics

The Increasing Population with Myelodysplastic Syndrome is Driving the Global Myelodysplastic Syndrome Treatment Market Growth

Cytogenetic abnormalities, molecular mutations, and morphologic and physiological abnormalities in the maturation and differentiation of one or more hematopoietic cell lines are all signs that myelodysplastic syndrome impacts hematopoiesis at the stem cell level. 

According to the Leukemia and Lymphoma Society, in the United States, about 20,000 new cases of myelodysplastic syndromes are diagnosed each year.  The prevalence of the disease, when compared to age, is approximately 3.4 per 100,000 people in the general population. The incidence rises noticeably among older patient populations. 

Based on information from Medicare billing records, the incidence for patients over 65 is approximately 65 instances per 100,000 patients. For those over 65, that rise is rather large. The average age of MDS patients is 71. Myelodysplastic syndromes are more likely to emerge in elderly patient populations. One of the risk factors is it. 

In addition, acute leukemia is more likely to develop in people with myelodysplastic syndrome and a large number of blasts in their bone marrow. The same chemotherapy treatment used for acute myeloid leukemia patients may be utilized to treat them. 

Side Effects Associated with Myelodysplastic Syndrome Medication are Hampering the Global Myelodysplastic Syndrome Treatment Market Growth

Side effects associated with myelodysplastic syndrome treatment are a significant challenge for the myelodysplastic syndrome treatment market, posing a threat to the industry's growth and profitability. Every treatment has potential negative effects. However, depending on the type of treatment employed and how a person responds to it, the type and severity will differ between individuals. In general, more severe side effects are linked to more extensive treatment. 

The side effects include bleeding or bruising, for instance, blood in our urine, feces, sputum, bleeding gums or a persistent nose bleed, a temperature of 38 0C or over (even if it returns to normal), and an episode of uncontrolled shivering (a rigor), nausea or vomiting that prevents from eating or drinking or taking patient’s normal medications, and severe diarrhea. All these side effects are restraining the market growth.

For more details on this reportRequest for Sample


Myelodysplastic Syndrome (MDS) Treatment Market Segment Analysis

The global myelodysplastic syndrome treatment market is segmented based on treatment type, end-user, and region.

The Chemotherapy Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period

The chemotherapy segment accounted for the highest market stake accounting for approximately 32.1% of the myelodysplastic syndrome treatment market in 2022. 

Powerful chemicals are injected into and passed through a patient's bloodstream during myelodysplastic syndrome chemotherapy to reach aberrant cells all over the patient's body. Some myelodysplastic syndrome patients get the same chemotherapy medications that are often used to treat leukemia since myelodysplastic syndrome has the potential to advance to leukemia.  

To kill cancer cells, chemotherapy is administered. The cancer treatment also destroys healthy cells, such as blood-forming cells. A treatment to replenish the blood-forming cells is a stem cell transplant. The patient's or a donor's bone marrow is harvested for its stem cells (immature blood cells), which are then frozen and kept in storage. 

These chemotherapeutic treatments for myelodysplastic syndrome can be used alone, in conjunction with other anticancer therapies, or with medications from different classes, such as those that target proteins involved in bone marrow and blood cell development. 

Source: DataM Intelligence Analysis (2023)


Myelodysplastic Syndrome (MDS) Treatment Market Geographical Penetration

North America Holds a Dominant Position in the Global Myelodysplastic Syndrome Treatment Market

North America is estimated to hold around 41.6% of the total market share throughout the forecast period. The aging population in the region is increasing, which is resulting in increasing demand for medications.

In addition,  well-established healthcare infrastructure, strong research and development efforts, advanced targeted therapies, access to advanced diagnostic technologies, patient advocacy and awareness, and creating a need for specialized myelodysplastic syndrome treatment and collaborations by the market players are the factors expected to boost the regional growth over the forecast period.

There are between 60,000 and 175,000 cases of myelodysplastic syndrome in the United States, according to the prevalence of the condition. In the United States, the number of new cases of myelodysplastic syndrome and myelodysplastic syndrome caused by treatment is increasing. People are living longer as a result of cancer treatment. Thus, from the above factors, the North American region is expected to hold the largest market share over the forecast period. 


Source: DataM Intelligence Analysis (2023)


Myelodysplastic Syndrome (MDS) Treatment Companies

The major global players in the market include AbbVie Inc., Accord Healthcare, Bristol-Myers Squibb, Jazz Pharmaceuticals Inc., Novartis AG, Lupin Pharmaceuticals, Otsuka America Pharmaceutical Inc., Onconova Therapeutics, Takeda Pharmaceutical Company Limited, and Astex Pharmaceuticals, Inc. among others.


COVID-19 Impact on Myelodysplastic Syndrome (MDS) Treatment Market

Russia-Ukraine Conflict Analysis

The Russia-Ukraine war have affected the myelodysplastic syndrome treatment market due to the burden of disease and the lack of healthcare facilities being impacted during times of geopolitical instability and economic uncertainty. 

The company’s ability to enter into agreements with strategic partners and other matters that could affect the availability or commercial potential of product candidates, business or economic disruptions caused by catastrophes or other events, including natural disasters or public health crises such as geopolitical risks, including the war between Russia and Ukraine. 

Artificial Intelligence Analysis:

Artificial intelligence (AI) is increasingly being used in the myelodysplastic syndrome treatment market to improve various aspects of the customer experience to forecast how each patient will react to various treatment options, AI models may analyze patient data, including genetic profiles, laboratory results, and treatment history. 

These forecasts can help medical professionals choose the best course of action for myelodysplastic syndrome patients, optimize outcomes, and reduce negative consequences.

Based on certain criteria, such as genetic mutations or disease characteristics, AI analysis can assist in identifying potential participants for clinical trials. AI algorithms may also examine trial data from the past to spot trends and gauge the likelihood that a trial would succeed, which can help researchers create more effective and focused clinical trials for myelodysplastic syndrome treatments. 

Key Developments

  • In February 2022, Syros Pharmaceuticals, engaged in the development of medicines that control the expression of genes, announced that the U.S. Food and Drug Administration has authorized orphan drug designation (ODD) to tamibarotene for the treatment of the myelodysplastic syndrome. For RARA-positive patients with newly diagnosed higher-risk MDS (HR-MDS), tamibarotene, an oral first-in-class selective retinoic acid receptor alpha (RAR) agonist, is now being studied in conjunction with azacitidine in the SELECT-MDS-1 Phase 3 trial.
  • In January 2022, Accord Healthcare, a pharmaceutical company, launched lenalidomide, available for the treatment of adult patients with multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, and follicular lymphoma, as either a monotherapy or combination therapy in the UK region. 

Why Purchase the Report?

  • To visualize the global myelodysplastic syndrome treatment market segmentation based on the treatment type, end-user, and region and understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development. 
  • Excel data sheet with numerous data points of myelodysplastic syndrome treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global myelodysplastic syndrome treatment market report would provide approximately 54 tables, 50 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

For more Pharmaceutical related reports, please click here

Buy this report
Single User
Multiple User
Enterprise User
Proceed to Buy
Request new version
What is the Projected CAGR value of the Respules Market?
Respules Market is expected to grow at a CAGR of 9.1% during the forecasting period 2023-2030.
Which Companies Are Included in the Myelodysplastic Syndrome (MDS) Treatment Market?
Contract Healthcare Ltd., Novartis, Bristol- Myers Squibb, Takeda Pharmaceutical Organization Limited, Onconova Therapeutics, Celgene Company, Sandoz, Inc., and AbbVie are among the firms causing the expansion of the marketplace.
Which region controlled the global market during 2023-2030?
North American region Controls the Myelodysplastic Syndrome (MDS) Treatment Market during 2023-2030.
Which is the fastest-growing region in the Myelodysplastic Syndrome (MDS) Treatment Market?
Among all regions, Asia Pacific is the fastest-growing market share during the forecast period.
Related Reports

Stem Cell Banking Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 April 18
Starting from



Animal Stem Cell Therapy Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 June 09
Starting from



Klinefelter Syndrome Treatment Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 January 19
Starting from



Premenstrual Syndrome Treatment Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 April 04
Starting from



Guillain-Barre Syndrome Treatment Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 September 28
Starting from



Marfan Syndrome Treatment Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 June 13
Starting from